Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
3.680
+0.010 (0.27%)
Apr 25, 2025, 4:00 PM EDT - Market closed

Company Description

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States.

Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy.

The company also develops LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy.

In addition, it is developing LX1001, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease.

The company has license agreement with Cornell University to conduct of the Phase 1/2 clinical trial of LX1001, as well as support the development of LX1004 program; research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate.

The company was founded in 2017 and is headquartered in New York, New York.

Lexeo Therapeutics, Inc.
Lexeo Therapeutics logo
Country United States
Founded 2017
IPO Date Nov 3, 2023
Industry Biotechnology
Sector Healthcare
Employees 72
CEO R. Townsend

Contact Details

Address:
345 Park Avenue South, 6th Floor
New York, New York 10010
United States
Phone 212 547 9879
Website lexeotx.com

Stock Details

Ticker Symbol LXEO
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $11.00
CIK Code 0001907108
CUSIP Number 52886X107
ISIN Number US52886X1072
Employer ID 85-4012572
SIC Code 2836

Key Executives

Name Position
R. Nolan Townsend Chief Executive Officer and Director
Dr. Eric Adler M.D. Chief Medical Officer and Head of Research
Jenny R. Robertson J.D. Chief Legal Officer
Dr. Ronald G. Crystal M.D. Co-Founder, Chief Scientific Advisor and Member of Scientific Advisory Board
Dr. Kyle Rasbach Ph.D., Pharm.D. Chief Financial Officer
Dr. Jose Manuel Otero Ph.D. Chief Technical Officer
Jordan M. Baumhardt Ph.D. Vice President of Corporate Development
Dr. Sandi See Tai M.D. Chief Development Officer
Leslie DiRisio Senior Vice President of Development Operations
Ryan McHenry Vice President and Corporate Controller

Latest SEC Filings

Date Type Title
Apr 7, 2025 8-K Current Report
Mar 24, 2025 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Mar 24, 2025 424B5 Filing
Mar 24, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 24, 2025 10-K Annual Report
Mar 24, 2025 8-K Current Report
Feb 19, 2025 144 Filing
Feb 19, 2025 144 Filing
Feb 19, 2025 144 Filing
Feb 19, 2025 144 Filing